JMP Securities analyst Silvan Tuerkcan downgrades Intellia Therapeutics (NASDAQ:NTLA) from Market Outperform to Market Perform.
JMP Securities Downgrades Intellia Therapeutics to Market Perform
JMP Securities analyst Silvan Tuerkcan downgrades Intellia Therapeutics (NASDAQ:NTLA) from Market Outperform to Market Perform.